Endo International plc company logo

# 1st Gen Model Endo International plc Pharmaceutical preparations

  • $11.65Last close price
    at 22-jun-2017
  • Subscribe >> Deal exit on
    June 23, 2017
    Deal entry on
    June 23, 2017
  • 2.41%Expected margin
  • 56.67% successful of 60 deals

ENDP

Model's trade recommendations -1.75% Return for period

-40.66% Annual return

$2.54B Market Cap

β 0.57  

ENDP

Model (following trade recommendations)

ENDP

Underlying stock

S&P 500

Index
Return for period -1.75%
-9.62%
1.78%
52wk return -48.91%
-26.45%
16.82%
52wk Range
9.87—24.18
2000.54—2399.63
Sortino ratio -1.19
Sharpe ratio -1.12
Norm. RMSE 1.14%
Downside risk 36.61%
Volatility 39.09%
  • BUY Analysts consensus recommendation

Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Endo International plc (ENDP) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for ENDP model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 222M
P/E 2.34
Shares Outstanding 223M
% Held by Insiders 0.70%
% Held by Institutions 93.30%
EPS (last reported FY) $4.73
EPS (last reported Q) $1.23
EPS, estimated (last reported Q) $1.12
Total revenues $4 B
Net income $-3 B